Literature DB >> 31092589

Non-classical monocyte homing to the gut via α4β7 integrin mediates macrophage-dependent intestinal wound healing.

Lena Schleier1, Maximilian Wiendl1, Markus F Neurath1, Sebastian Zundler1, Karin Heidbreder1, Marie-Theres Binder1, Raja Atreya1, Timo Rath1, Emily Becker1, Anja Schulz-Kuhnt1, Annette Stahl1, Lisa Lou Schulze1, Karen Ullrich1, Simon F Merz2, Lea Bornemann2, Matthias Gunzer2, Alastair J M Watson3, Clemens Neufert1, Imke Atreya1.   

Abstract

OBJECTIVE: To study the role of α4β7 integrin for gut homing of monocytes and to explore the biological consequences of therapeutic α4β7 inhibition with regard to intestinal wound healing.
DESIGN: We studied the expression of homing markers on monocyte subsets in the peripheral blood and on macrophage subsets in the gut of patients with IBD and controls with flow cytometry and immunohistochemistry. Integrin function was addressed with dynamic adhesion assays and in vivo gut homing assays. In vivo wound healing was studied in mice deficient for or depleted of α4β7 integrin.
RESULTS: Classical and non-classical monocytes were clearly dichotomous regarding homing marker expression including relevant expression of α4β7 integrin on human and mouse non-classical monocytes but not on classical monocytes. Monocyte-expressed α4β7 integrin was functionally important for dynamic adhesion to mucosal vascular addressin cell adhesion molecule 1 and in vivo gut homing. Impaired α4β7-dependent gut homing was associated with reduced (effect size about 20%) and delayed wound healing and suppressed perilesional presence of wound healing macrophages. Non-classical monocytes in the peripheral blood were increased in patients with IBD under clinical treatment with vedolizumab.
CONCLUSION: In addition to reported effects on lymphocytes, anti-α4β7 therapy in IBD also targets non-classical monocytes. Impaired gut homing of such monocytes might lead to a reduction of wound healing macrophages and could potentially explain increased rates of postoperative complications in vedolizumab-treated patients, which have been observed in some studies. © Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  Crohn’s disease; gut immunology; inflammatory bowel disease; surgery for IBD; ulcerative colitis

Mesh:

Substances:

Year:  2019        PMID: 31092589     DOI: 10.1136/gutjnl-2018-316772

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  29 in total

1.  Circulating α4β7+ Memory T Cells in Pediatric IBD Patients Express a Polyclonal T Cell Receptor Repertoire.

Authors:  Adir Gamliel; Lael Werner; Marina Pinsker; Naomi Salamon; Batia Weiss; Dror S Shouval
Journal:  Clin Exp Gastroenterol       Date:  2020-10-02

Review 2.  Gut immune cell trafficking: inter-organ communication and immune-mediated inflammation.

Authors:  Sebastian Zundler; Claudia Günther; Andreas E Kremer; Mario M Zaiss; Veit Rothhammer; Markus F Neurath
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2022-08-09       Impact factor: 73.082

3.  Deciphering the vedolizumab dosing conundrum in IBD: when less is more.

Authors:  Timon Erik Adolph; Britta Siegmund
Journal:  Gut       Date:  2021-09-08       Impact factor: 31.793

Review 4.  Mucosal vaccine delivery: A focus on the breakthrough of specific barriers.

Authors:  Mengwen Huang; Miaomiao Zhang; Hongbin Zhu; Xiaojiao Du; Jun Wang
Journal:  Acta Pharm Sin B       Date:  2022-07-06       Impact factor: 14.903

Review 5.  Immune Cell Circuits in Mucosal Wound Healing: Clinical Implications.

Authors:  Sebastian Zundler; Verena Tauschek; Markus F Neurath
Journal:  Visc Med       Date:  2020-03-13

6.  Increased Risk of Infections with Anti-TNF Agents in Patients with Crohn's Disease After Elective Surgery: Meta-Analysis.

Authors:  Jurij Hanzel; Ahmed Almradi; Alexandra C Istl; Mei Lucy Yang; Katherine A Fleshner; Claire E Parker; Leonardo Guizzetti; Christopher Ma; Siddharth Singh; Vipul Jairath
Journal:  Dig Dis Sci       Date:  2021-02-26       Impact factor: 3.199

7.  β6 integrinosis: a new lethal autosomal recessive ITGB6 disorder leading to impaired conformational transitions of the αVβ6 integrin receptor.

Authors:  Andreas C Jenke; Jan Postberg; Patrick Weil; Rhea van den Bruck; Thomas Ziegenhals; Stefan Juranek; Daniel Goedde; Valerie Orth; Stefan Wirth
Journal:  Gut       Date:  2019-06-14       Impact factor: 23.059

Review 8.  Biologics and surgical outcomes in Crohn's disease: is there a direct relationship?

Authors:  Abel Botelho Quaresma; Takayuki Yamamoto; Paulo Gustavo Kotze
Journal:  Therap Adv Gastroenterol       Date:  2020-07-16       Impact factor: 4.409

Review 9.  Resolution of Inflammation and Gut Repair in IBD: Translational Steps Towards Complete Mucosal Healing.

Authors:  Gwo-Tzer Ho; Jennifer A Cartwright; Emily J Thompson; Calum C Bain; Adriano G Rossi
Journal:  Inflamm Bowel Dis       Date:  2020-07-17       Impact factor: 5.325

10.  Baseline levels of dynamic CD4+ T cell adhesion to MAdCAM-1 correlate with clinical response to vedolizumab treatment in ulcerative colitis: a cohort study.

Authors:  Clarissa Allner; Michaela Melde; Emily Becker; Friederike Fuchs; Laura Mühl; Entcho Klenske; Lisa Müller; Nadine Morgenstern; Konstantin Fietkau; Simon Hirschmann; Raja Atreya; Imke Atreya; Markus F Neurath; Sebastian Zundler
Journal:  BMC Gastroenterol       Date:  2020-04-15       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.